Key result
APOA5 rs3135506 polymorphism is linked to ~2.8-fold higher risk of metabolic syndrome.
Why the study?
Genetic factors contribute to metabolic syndrome development, motivating evaluation of APOA5 and CETP gene polymorphisms and susceptibility to metabolic syndrome and its components in a Moroccan population.
Are APOA5 rs3135506 and CETP rs708272 polymorphisms associated with susceptibility to metabolic syndrome and its components in a Moroccan population?
Case-Control (n=274)
Are APOA5 rs3135506 and CETP rs708272 polymorphisms associated with susceptibility to metabolic syndrome and its components in a Moroccan population?
The APOA5 rs3135506 polymorphism and specific APOA5-CETP combined genotypes are strongly associated with metabolic syndrome and its cardiometabolic components in a Moroccan cohort, suggesting potential utility as genetic risk biomarkers.
APOA5 rs3135506 association with metabolic syndrome risk should not yet alter practice; leaves open hypothesis-generating role for prospective validation.
Background: Metabolic syndrome (MetS) is a multifactorial condition and a major public health concern due to its strong association with cardiovascular disease and type 2 diabetes. Genetic factors contribute to its development. This study aims to evaluate the association between polymorphisms in genes APOA5 and CETP and susceptibility to MetS and its components in a Moroccan population. Methods: A case–control study was conducted, including 136 MetS patients and 138 controls recruited from the Doukkala region (Morocco). The APOA5 rs3135506 (C>G) and CETP rs708272 (G>A) polymorphisms were genotyped using PCR-RFLP. Results: The APOA5 rs3135506 polymorphism was significantly associated with increased MetS risk. The CG and GG genotypes conferred 2.39-fold (OR = 2.39; p = 0.0008) and 7.17-fold (OR = 7.17; p = 0.0007) higher risks, respectively, with significant associations also observed under dominant (OR = 2.76; p < 0.0001), recessive (OR = 4.79; p = 0.006), and allelic (OR = 2.36; p < 0.0001) models. The GG genotype was also associated with general and abdominal obesity, hypertension, and hyperglycemia, whereas the CG genotype was associated with dyslipidemia. For CETP rs708272, the AA genotype was associated with increased MetS risk (OR = 3.31; p = 0.0078), with significant associations under dominant (OR = 1.81; p = 0.0160), recessive (OR = 2.80; p = 0.0185), and allelic (OR = 1.81; p = 0.0023) models. However, these associations were no longer significant after adjustment for age and sex. Combined genotype analysis revealed increased MetS risk for the CG–GG, CG–GA, and GG–AA combinations (OR = 4.64, 2.98, and 7.35, respectively). Conclusion: The APOA5 rs3135506 and CETP rs708272 polymorphisms may contribute to MetS susceptibility in the Moroccan population, with certain combined genotypes associated with increased risk. These findings support their potential as genetic biomarkers for early risk assessment but require confirmation in larger studies.
No takes yet. Share an insight, caveat, or question.
Farhane et al. (2026) conducted a case-control in Metabolic syndrome (n=274). APOA5 rs3135506 (C>G) and CETP rs708272 (G>A) polymorphisms vs. Wild-type reference genotypes/alleles in 138 controls without metabolic syndrome was evaluated on Susceptibility to metabolic syndrome (OR 2.76, p=< 0.0001). APOA5 rs3135506 polymorphism increased metabolic syndrome risk (dominant OR 2.76, p<0.0001; GG OR 7.17, p=0.0007), while CETP rs708272 lost significance after age/sex adjustment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: